BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36730269)

  • 21. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.
    Li H; Velasco-Miguel S; Vass WC; Parada LF; DeClue JE
    Cancer Res; 2002 Aug; 62(15):4507-13. PubMed ID: 12154062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
    Daginakatte GC; Gianino SM; Zhao NW; Parsadanian AS; Gutmann DH
    Cancer Res; 2008 Dec; 68(24):10358-66. PubMed ID: 19074905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving outcomes for neurofibromatosis 1-associated brain tumors.
    Brossier NM; Gutmann DH
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
    Ullrich NJ; Prabhu SP; Reddy AT; Fisher MJ; Packer R; Goldman S; Robison NJ; Gutmann DH; Viskochil DH; Allen JC; Korf B; Cantor A; Cutter G; Thomas C; Perentesis JP; Mizuno T; Vinks AA; Manley PE; Chi SN; Kieran MW
    Neuro Oncol; 2020 Oct; 22(10):1527-1535. PubMed ID: 32236425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain tumors in Neurofibromatosis type 1.
    Costa AA; Gutmann DH
    Neurooncol Adv; 2019; 1(1):vdz040. PubMed ID: 32642668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
    Watson AL; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
    Oncotarget; 2014 Mar; 5(6):1502-14. PubMed ID: 24681606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
    Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
    Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
    Dang I; DeVries GH
    J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
    Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y
    Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.
    Hegedus B; Hughes FW; Garbow JR; Gianino S; Banerjee D; Kim K; Ellisman MH; Brantley MA; Gutmann DH
    J Neuropathol Exp Neurol; 2009 May; 68(5):542-51. PubMed ID: 19525901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.
    Turbyville TJ; Gürsel DB; Tuskan RG; Walrath JC; Lipschultz CA; Lockett SJ; Wiemer DF; Beutler JA; Reilly KM
    Mol Cancer Ther; 2010 May; 9(5):1234-43. PubMed ID: 20442305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights.
    Khatua S; Gutmann DH; Packer RJ
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29049847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.
    Landry JP; Schertz KL; Chiang YJ; Bhalla AD; Yi M; Keung EZ; Scally CP; Feig BW; Hunt KK; Roland CL; Guadagnolo A; Bishop AJ; Lazar AJ; Slopis JM; McCutcheon IE; Torres KE
    JAMA Netw Open; 2021 Mar; 4(3):e210945. PubMed ID: 33734413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofibromatosis type 1 and malignancy in childhood.
    Varan A; Şen H; Aydın B; Yalçın B; Kutluk T; Akyüz C
    Clin Genet; 2016 Mar; 89(3):341-5. PubMed ID: 26073032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.
    Alexandru O; Sevastre AS; Castro J; Artene SA; Tache DE; Purcaru OS; Sfredel V; Tataranu LG; Dricu A
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.
    Osum SH; Watson AL; Largaespada DA
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
    Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
    Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.